WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK.
Best Pract Res Clin Rheumatol. 2009 Dec;23(6):711-26. doi: 10.1016/j.berh.2009.09.002.
Fractures are the clinical consequence of osteoporosis and are a major cause of morbidity and mortality worldwide. Although treatments are available that have been shown to decrease the risk of fracture, problems arise in identifying individuals at high risk of fracture so that intervention can be effectively targeted. Practice guidelines, available in many countries, differ markedly in approach, but generally recommend treatments on the basis of a previous fragility fracture and a defined threshold for bone mineral density (BMD). Recent developments in fracture risk assessment include the availability of the FRAX tool by the World Health Organization (WHO) Collaborating Centre for Metabolic Bone Diseases at Sheffield, UK, that integrates the weight of clinical risk factors for fracture risk with or without information on BMD and computes the 10-year probability of fracture. The tool increases sensitivity without trading specificity and is now being used in the re-appraisal of clinical guidelines.
骨折是骨质疏松症的临床后果,也是全球发病率和死亡率的主要原因。尽管已经有研究表明某些治疗方法可以降低骨折风险,但在确定高骨折风险人群方面仍存在问题,以便能够有效地进行干预。许多国家都有实践指南,但方法差异很大,一般根据既往脆性骨折和骨密度(BMD)的定义阈值推荐治疗方法。骨折风险评估的最新进展包括英国谢菲尔德代谢性骨疾病世界卫生组织(WHO)合作中心提供的 FRAX 工具,该工具将骨折风险的临床危险因素的权重与 BMD 信息相结合或不结合,并计算出 10 年骨折概率。该工具在不影响特异性的情况下提高了敏感性,目前正在重新评估临床指南。